Literature DB >> 22912356

Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma.

Tonia Cenci1, Maurizio Martini, Nicola Montano, Quintino G D'Alessandris, Maria Laura Falchetti, Daniela Annibali, Mauro Savino, Federico Bianchi, Francesco Pierconti, Sergio Nasi, Roberto Pallini, Luigi Maria Larocca.   

Abstract

Although the c-Myc oncogene is frequently deregulated in human cancer, its involvement in the pathogenesis of glioblastoma is not clear. We conducted immunohistochemical analysis of the expression of c-Myc, polycomb ring finger oncogene (BMI1), and acetylation of the lysine 9 (H3K9Ac) of histone 3 in 48 patients with glioblastoma who underwent surgery followed by radiotherapy and temozolomide treatment. The expression of c-Myc, BMI1, and H3K9ac was correlated with clinical characteristics and outcome. We found that overexpression of c-Myc was significantly associated with that of BMI1 (P = .009), and that patients who harbored glioblastomas overexpressing c-Myc and BMI1 showed significantly longer overall survival (P < .0001 and P = .0009, respectively). Our results provide the first evidence of the prognostic value of c-Myc and associated genes in patients with glioblastoma. The favorable effect of c-Myc and BMI1 expression on survival is likely mediated by the sensitization of cancer cells to radiotherapy and temozolomide through the activation of apoptotic pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22912356     DOI: 10.1309/AJCPRXHNJQLO09QA

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  23 in total

1.  LEF1 regulates glioblastoma cell proliferation, migration, invasion, and cancer stem-like cell self-renewal.

Authors:  Xingchun Gao; Yajing Mi; Yue Ma; Weilin Jin
Journal:  Tumour Biol       Date:  2014-08-16

Review 2.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

3.  CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma.

Authors:  M K Sibin; Dhananjaya I Bhat; K V L Narasingarao; Ch Lavanya; G K Chetan
Journal:  Tumour Biol       Date:  2015-04-29

4.  Overexpression and lack of copy number variation in the BMI-1 gene in human glioma.

Authors:  Sibin Madathan Kandy; Dhananjaya Ishwara Bhat; Lavanya Choppavarapu; Arati Suvatha; Chetan Ghati Kasturirangan
Journal:  Oncol Lett       Date:  2015-09-08       Impact factor: 2.967

Review 5.  What is the clinical value of cancer stem cell markers in gliomas?

Authors:  Rikke Hedegaard Dahlrot; Simon Kjær Hermansen; Steinbjørn Hansen; Bjarne Winther Kristensen
Journal:  Int J Clin Exp Pathol       Date:  2013-02-15

6.  CD133 and BMI1 expressions and its prognostic role in primary glioblastoma.

Authors:  M K Sibin; C H Lavanya; Dhananjaya I Bhat; Narasinga Rao; N Geethashree; W Vibhuti; G K Chetan
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

Review 7.  Astrocyte elevated gene-1 (AEG-1) and the A(E)Ging HIV/AIDS-HAND.

Authors:  Neha Vartak-Sharma; Shruthi Nooka; Anuja Ghorpade
Journal:  Prog Neurobiol       Date:  2016-04-14       Impact factor: 11.685

Review 8.  Polycomb group proteins and MYC: the cancer connection.

Authors:  Leonidas Benetatos; George Vartholomatos; Eleftheria Hatzimichael
Journal:  Cell Mol Life Sci       Date:  2013-07-30       Impact factor: 9.261

9.  Nuclear-encoded cytochrome c oxidase subunit 4 regulates BMI1 expression and determines proliferative capacity of high-grade gliomas.

Authors:  Claudia R Oliva; Tahireh Markert; G Yancey Gillespie; Corinne E Griguer
Journal:  Oncotarget       Date:  2015-02-28

10.  BMI1, stem cell factor acting as novel serum-biomarker for Caucasian and African-American prostate cancer.

Authors:  Hifzur Rahman Siddique; Aijaz Parray; Weixiong Zhong; R Jeffery Karnes; Eric J Bergstralh; Shahriar Koochekpour; Johng S Rhim; Badrinath R Konety; Mohammad Saleem
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.